Halozyme to Present at Roth Capital Growth Conference

SAN DIEGO--(BUSINESS WIRE)--Feb. 11, 2009-- Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced that David A. Ramsay, Halozyme's CFO will present at the Roth Capital Partners 21^stAnnual Growth Stock Conference on Tuesday, February 17, 2009 at 4:00 p.m. PST (7:00 p.m. EST) at the Ritz-Carlton Laguna Niguel in Dana Point, California.

Interested parties can access a live audio webcast and accompanying slides of the company presentation via the Internet by visiting the Investor Relations section of Halozyme's Web site at https://www.halozyme.com. An archived presentation will be available on the Halozyme Web site for 30 days following the presentation date.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID. Halozyme's research pipeline candidates target significant areas of unmet medical need. For more information visit https://www.halozyme.com.

Source: Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.Robert H. UhlSenior Director, Investor [email protected]